Boehringer
Top stories
Latest
- Experimental Survodutide Cut Weight Up to 13.1% in Adults with Type 2 Diabetes in Boehringer's Phase 3 Trialmedicaldaily.com · 2026-10-02 02:38 UTC · story
- No IPO: Boehringer remains independentapotheke-adhoc.de · 2026-09-30 17:22 UTC · 1 more reports
